The effect of chemically modified alginates on macrophage phenotype and biomolecule transport
Hannah C. Bygd
Department of Materials Science and Engineering, Iowa State University, Ames, Iowa, 50011
Search for more papers by this authorCorresponding Author
Kaitlin M. Bratlie
Department of Materials Science and Engineering, Iowa State University, Ames, Iowa, 50011
Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa, 50011
Division of Materials Science & Engineering, Ames National Laboratory, Ames, Iowa, 50011
Correspondence to: Kaitlin M. Bratlie; e-mail: [email protected]Search for more papers by this authorHannah C. Bygd
Department of Materials Science and Engineering, Iowa State University, Ames, Iowa, 50011
Search for more papers by this authorCorresponding Author
Kaitlin M. Bratlie
Department of Materials Science and Engineering, Iowa State University, Ames, Iowa, 50011
Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa, 50011
Division of Materials Science & Engineering, Ames National Laboratory, Ames, Iowa, 50011
Correspondence to: Kaitlin M. Bratlie; e-mail: [email protected]Search for more papers by this authorAbstract
Macrophage (MΦ) reprogramming has received significant attention in applications such as cancer therapeutics and tissue engineering where the host immune response to biomaterials is crucial in determining the success or failure of an implanted device. Polymeric systems can potentially be used to redirect infiltrating M1 MΦs toward a proangiogenic phenotype. This work exploits the concept of MΦ reprogramming in the engineering of materials for improving the longevity of tissue engineering scaffolds. We have investigated the effect of 13 different chemical modifications of alginate on MΦ phenotype. Markers of the M1 response—tumor necrosis factor-α (TNF-α) and inducible nitric oxide synthase—and the M2 response—arginase—were measured and used to determine the ability of the materials to alter MΦ phenotype. It was found that some modifications were able to reduce the pro-inflammatory response of M1 MΦs, others appeared to amplify the M2 phenotype, and the results for two materials suggested they were able to reprogram a MΦ population from M1 to M2. These findings were supplemented by studies done to examine the permselectivity of the materials. Diffusion of TNF-α was completely prevented through some of these materials, while up to 84% was found to diffuse through others. The diffusion of insulin through the materials was statistically consistent. These results suggest that the modification of these materials might alter mass transport in beneficial ways. The ability to control polarization of MΦ phenotypes with immunoprotective materials has the potential to augment the success of tissue engineering scaffolds. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1707–1719, 2016.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Filename | Description |
---|---|
jbma35700-sup-0001-suppinfo.docx98.6 MB |
Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Daneman D. Type 1 diabetes. Lancet 2006; 367: 847–858.
- 2Bratlie KM, York RL, Invernale Ma, Langer R, Anderson DG. Materials for diabetes therapeutics. Adv Healthc Mater 2012; 1: 267–284.
- 3 American Diabetes Association. Statistics About Diabetes. Available at: http://www.diabetes.org/diabetes-basics/statistics/?loc=superfooter. 2014.
- 4 Type 1 Diabetes Facts. Available at: http://jdrf.org/about-jdrf/fact-sheets/type-1-diabetes-facts/. 2014.
- 5Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221–229.
- 6Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980; 210: 908–910.
- 7Calafiore R, Basta G. Clinical application of microencapsulated islets: Actual prospectives on progress and challenges. Adv Drug Deliv Rev 2014; 6768: 84–92.
- 8Jacobs-Tulleneers-Thevissen D, Chintinne M, Ling Z, Gillard P, Schoonjans L, Delvaux G, Strand BL, Gorus F, Keymeulen B, Pipeleers D. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 2013; 56: 1605–1614.
- 9Paredes Juárez GA, Spasojevic M, Faas MM, de Vos P. Immunological and technical considerations in application of alginate-based microencapsulation systems. Front Bioeng Biotechnol 2014; 2: 26
- 10Scharp DW, Marchetti P. Encapsulated islets for diabetes therapy: History, current progress, and critical issues requiring solution. Adv Drug Deliv Rev 2014; 6768: 35–73.
- 11Ryan EA, et al. Five-Year Follow-Up After Clinical Islet Transplantation. Diabetes 2005; 54: 2060–2069.
- 12Basta G, et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: Four cases. Diabetes Care 2011; 34: 2406–2409.
- 13Ontanucci MPIAM, et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: First two cases. Diabetes Care 2006; 29: 137–138.
- 14Lu YC, et al. Designing compartmentalized hydrogel microparticles for cell encapsulation and scalable 3D cell culture. J Mater Chem B 2015; 3: 353–360.
- 15Song W, et al. Nanofibrous microposts and microwells of controlled shapes and their hybridization with hydrogels for cell encapsulation. ACS Appl Mater Interfaces 2014; 6: 7038–7044.
- 16Champion JA, Walker A, Mitragotri S. Role of Particle Size in Phagocytosis of Polymeric Microspheres. Parm Res 2008; 25: 1815–1821.
- 17Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 2009; 26: 244–249.
- 18Chen JP, Chu IM, Shiao MY, Hsu BRS, Fu SH. Microencapsulation of Islets in PEG-Amine Modified Alginate- Poly (L-Lysine) -Alginate Microcapsules for Constructing Bioartificial Pancreas. J Ferment Bioeng 1998; 86: 185–190.
- 19Mallett AG, Korbutt GS. Alginate modification improves long-term survival and function of transplanted encapsulated islets. Tissue Eng Part A 2009; 15: 1301–1309.
- 20de Vos P, de Haan BJ, Wolters GHJ, Strubbe JH, van Schilfgaarde R. Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets. Diabetologia 1997; 40: 262–270.
- 21Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012; 37: 106–126.
- 22Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev 2012; 64: 194–205.
- 23Constantinidis I, et al. Non-Invasive Evaluation of Algiante/Poly-L-Lysine/Alginate Microcapsules by Magnetic Resonance Microscopy. Biomaterials 2007; 28: 2438–2445.
- 24Zan X, Garapaty A, Champion JA. Engineering polyelectrolyte capsules with independently controlled size and shape. Langmuir 2015;150626153539009. doi:10.1021/acs.langmuir.5b01578
- 25de Vos P, et al. Long-term biocompatibility, chemistry, and function of microencapsulated pancreatic islets. Biomaterials 2003; 24: 305–312.
- 26Tam SK, et al. Biocompatibility and physicochemical characteristics of alginate-polycation microcapsules. Acta Biomater 2011; 7: 1683–1692.
- 27De Vos P, De Haan B, Van Schilfgaarde R. Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. Biomaterials 1997; 18: 273–278.
- 28Cramer H, et al. Biocompatible alginate from freshly collected Laminaria pallida for implantation. Appl Microbiol Biotechnol 2000; 53: 224–229.
- 29Petruzzo P, et al. Development of biocompatible barium alginate microcapsules. Transplant Proc 1997; 1345: 2129–2130.
- 30Schneider S, et al. Biocompatibility of alginates for grafting: Impact of alginate molecular weight. Artif Cells Blood Substit Biotechnol 2003; 31: 383–394.
- 31Zimmermann U, et al. A novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation. Ann N Y Acad Sci 2006; 944: 199–215.
- 32Steele JaM, Hallé JP, Poncelet D, Neufeld RJ. Therapeutic cell encapsulation techniques and applications in diabetes. Adv Drug Deliv Rev 2014; 6768: 74–83.
- 33Paredes-Juarez GA, de Haan B, Faas M, de Vos P. A technology platform to test the efficacy of purification of alginate. Materials (Basel) 2014; 7: 2087–2103.
- 34Lee C, et al. Bioinspired, calcium-free alginate hydrogels with tunable physical and mechanical properties and improved biocompatibility. Biomacromolecules 2013; 14: 2004–2013.
- 35Orive G, Hernandez RM, Gascon AR. Survival of different cell lines in alginate-agarose microcapsules. Eur J Pharm Sci 2003; 18: 23–30.
- 36Yang JS, Xie YJ, He W. Research progress on chemical modification of alginate: A review. Carbohydr Polym 2011; 84: 33–39.
- 37Pawar SN, Edgar KJ. Alginate derivatization: a review of chemistry, properties and applications. Biomaterials 2012; 33: 3279–3305.
- 38Nafea EH, Marson A, Poole-Warren LA, Martens PJ. Immunoisolating semi-permeable membranes for cell encapsulation: Focus on hydrogels. J Control Release 2011; 154: 110–122.
- 39Paredes-Juarez GA, de Haan BJ, Faas MM, de Vos P. The role of pathogen-associated molecular patterns in inflammatory responses against alginate based microcapsules. J Control Release 2013; 172: 983–992.
- 40Piro S, et al. Bovine islets are less susceptible than human islets to damage by human cytokines. Transplantation 2001; 71: 21–26.
- 41de Vos P, Faas MM, Strand B, Calafiore R. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 2006; 27: 5603–5617.
- 42de Vos P, Marchetti P. Encapsulation of pancreatic islets for transplantation in diabetes: The untouchable islets. Trends Mol Med 2002; 8: 363–366.
- 43Oyaas J, Storrø I, Svendsen H, Levine DW. The effective diffusion coefficient and the distribution constant for small molecules in calcium-alginate gel beads. Biotechnol Bioeng 1995; 47: 492–500.
- 44Ha J, Engler CR, Lee SJ. Determination of diffusion coefficients and diffusion characteristics for chlorferon and diethylthiophosphate in Ca-alginate gel beads. Biotechnol Bioeng 2008; 100: 698–706.
- 45de Vos P, et al. Association between macrophage activation and function of micro-encapsulated rat islets. Diabetologia 2003; 46: 666–673.
- 46Bygd HC, Forsmark KD, Bratlie KM. The significance of macrophage phenotype in cancer and biomaterials. Clin Transl Med 2014; 3: 62.
- 47Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep 2014; 6: 1–13
- 48Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41: 14–20.
- 49Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013; 229: 176–185.
- 50Biswas SK, Chittezhath M, Shalova IN, Lim JY. Macrophage polarization and plasticity in health and disease. Immunol Res 2012; 53: 11–24.
- 51McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF. Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci U S A 2013; 110: 17253–17258.
- 52McWhorter FY, Davis CT, Liu WF. Physical and mechanical regulation of macrophage phenotype and function. Cell Mol Life Sci 2014; 72: 1303–1316.
- 53Walkey CD, Olsen JB, Guo H, Emili A, Chan WCW. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 2012; 134: 2139–2147.
- 54Bartneck M, Heffels KH, Bovi M, Groll J, Zwadlo-Klarwasser G. The role of substrate morphology for the cytokine release profile of immature human primary macrophages. Mater Sci Eng C Mater Biol Appl 2013; 33: 5109–5114.
- 55Bartneck M, et al. Induction of specific macrophage subtypes by defined micro-patterned structures. Acta Biomater 2010; 6: 3864–7382.
- 56Doshi N, Mitragotri S. Macrophages recognize size and shape of their targets. PLoS One 2010; 5: e10051
- 57 ASTM Standard F2259. Standard Test Method for Determining the Chemical Composition and Sequence in Alginate by Proton Nuclear Magnetic Resonance (1H NMR). ASTM International. 2012. Conshohocken, Pennsylvania. doi:10.1520/F2259-10R12E01.Copyright.
- 58Grasdalen H, Larsen B, Smidsrod O. 13C N.M.R. studies of monomeric composition and sequence in alginate. Carbohydr Res 1981; 89: 179–191.
- 59Davis TA, et al. H-NMR Study of Na Alginates Extracted from Sargassum spp. in Relation to Metal Biosorption. Appl Biochem Biotechnol 2003; 110: 75–90.
- 60Levinson SS. Kinetic centrifugal analyzer and manual determination of serum urea nitrogen, with use of o-phthaldialdehyde reagent. Clin Chem 1978; 24: 2199–2202.
- 61Preitner F, et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 2004; 113: 635–645.
- 62Kulseng B, Thu B, Espevik T, Skjak-Braek G. Alginate polylysine microcapsules as immune barrier: Permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplant 1997; 6: 387–394.
- 63Xu Y, Zhan C, Fan L, Wang L, Zheng H. Preparation of dual crosslinked alginate-chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery system. Int J Pharm 2007; 336: 329–337.
- 64Simsek-ege FA, Bond GM, Stringer J. Polyelectrolye complex formation between alginate and chitosan as a function of pH. J Appl Polym Sci 2003; 88: 346–351.
- 65Fernandez-Hervas MJ, Holgado MA, Fini A, Fell JT. In vitro evaluation of alginate beads of a diclofenac salt. J Pharm 1998; 163: 23–34.
- 66Gonzalez-Rodriguez ML, Holgado MA, Sanchez-Lafuente C, Rabasco AM, Fini A. Alginate/chitosan particulate systems for sodium diclofenac release. Int J Pharm 2002; 232: 225–234.
- 67Singh AV. A DSC study of some biomaterials relevant to pharmaceutical industry. J Therm Anal. Calorim 2012; 112: 791–793.
- 68Smitha B, Sridhar S, Khan AA. Chitosan–sodium alginate polyion complexes as fuel cell membranes. Eur Polym J 2005; 41: 1859–1866.
- 69LeRoux MA, Guilak F, Setton LA. Compressive and shear properties of alginate gel: Effects of sodium ions and alginate concentration. J Biomed Mater Res 1999; 47: 46–53.
10.1002/(SICI)1097-4636(199910)47:1<46::AID-JBM6>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- 70Kuo CK, Ma PX. Ionically crosslinked alginate hydrogels as scaffolds for tissue engineering: Part 1. Structure, gelation rate and mechanical properties. Biomaterials 2001; 22: 511–521.
- 71Shen M, Garcia I, Maier RV, Horbett TA. Effects of adsorbed proteins and surface chemistry on foreign body giant cell formation, tumor necrosis factor alpha release and procoagulant activity of monocytes. J Biomed Mater Res A 2004; 70: 533–541.
- 72Kvist PH, et al. Biocopatibility of electrochemical glucose sensors impanted in the subcutis of pigs. Diabetes Technol Ther 2006; 8: 463–475.
- 73Ward WK. A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis. J Diabetes Sci Technol 2008; 2: 768–777.
- 74Kaklamani G, Cheneler D, Grover LM, Adams MJ, Bowen J. Mechanical properties of alginate hydrogels manufactured using external gelation. J Mech Behav Biomed Mater 2014; 36: 135–142.
- 75Li L, et al. Drug release characteristics from chitosan-alginate matrix tablets based on the theory of self-assembled film. Int J Pharm 2013; 450: 197–207.
- 76Capone SH, et al. Impact of alginate composition: from bead mechanical properties to encapsulated HepG2/C3A cell activities for in vivo implantation. PLoS One 2013; 8: e62032
- 77Ponce S, et al. Chemistry and the biological response against immunoisolating alginate-polycation capsules of different composition. Biomaterials 2006; 27: 4831–4839.
- 78Wang D, Phan N, Isely C, Bruene L, Bratlie KM. Effect of surface modification and macrophage phenotype on particle internalization. Biomacromolecules 2014; 15: 4102–4110.
- 79Akilbekova D, Philiph R, Graham A, Bratlie KM. Macrophage reprogramming: influence of latex beads with various functional groups on macrophage phenotype and phagocytic uptake in vitro. J Biomed Mater Res Part A 2015; 103: 262–268.
- 80Collier TO, Anderson JM. Protein and surface effects on monocyte and macrophage adhesion, maturation, and survival. J Biomed Mater Res 2002; 60: 487–496.
- 81Zaveri TD, et al. Contributions of surface topography and cytotoxicity to the macrophage response to zinc oxide nanorods. Biomaterials 2010; 31: 2999–3007.